Literature DB >> 23711406

Fine tuning type I interferon responses.

Paul J Hertzog1, Bryan R G Williams.   

Abstract

Interferon responses are balanced between protection against pathogens and other disease agents versus toxicity and development of chronic diseases. Optimal outcomes are achieved by regulating the nature, strength and duration of Interferon (IFN) production, IFN-receptor interaction and signalling pathways modulated in a manner appropriate for particular target cells. Modification of cell behaviour is mediated by regulation of positive and negative signalling pathways and by proteins encoded by selected groups of IFN-regulated genes. Understanding how these pathways are regulated and how to measure them by biomarkers or gene signatures will enable us to better understand the role of IFN pathways in the pathogenesis of infectious and inflammatory diseases and cancer. This will lead to improved patient stratification and disease treatment.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiviral; Innate Immunity; Interferons; STATs; Signal transduction

Mesh:

Substances:

Year:  2013        PMID: 23711406     DOI: 10.1016/j.cytogfr.2013.04.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  58 in total

1.  The E3 ubiquitin ligase MARCH1 regulates antimalaria immunity through interferon signaling and T cell activation.

Authors:  Jian Wu; Lu Xia; Xiangyu Yao; Xiao Yu; Keyla C Tumas; Wenxiang Sun; Yang Cheng; Xiao He; Yu-Chih Peng; Brajesh K Singh; Cui Zhang; Chen-Feng Qi; Silvia Bolland; Sonja M Best; Channe Gowda; Ruili Huang; Timothy G Myers; Carole A Long; Rong-Fu Wang; Xin-Zhuan Su
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-30       Impact factor: 11.205

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells.

Authors:  Sara Palchetti; Donatella Starace; Paola De Cesaris; Antonio Filippini; Elio Ziparo; Anna Riccioli
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

4.  Monitoring activation of the antiviral pattern recognition receptors RIG-I and PKR by limited protease digestion and native PAGE.

Authors:  Michaela Weber; Friedemann Weber
Journal:  J Vis Exp       Date:  2014-07-29       Impact factor: 1.355

5.  An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling.

Authors:  Chuantao Fang; Jian Li; Sixian Qi; Yubin Lei; Yan Zeng; Pengcheng Yu; Zhaolan Hu; Yufeng Zhou; Yulong Wang; Ruping Dai; Jin Li; Shenglin Huang; Pinglong Xu; Kang Chen; Chen Ding; Fa-Xing Yu
Journal:  EMBO Rep       Date:  2019-04-11       Impact factor: 8.807

6.  Primary familial brain calcification: update on molecular genetics.

Authors:  Ilaria Taglia; Vincenzo Bonifati; Andrea Mignarri; Maria Teresa Dotti; Antonio Federico
Journal:  Neurol Sci       Date:  2015-02-17       Impact factor: 3.307

7.  Negative regulation of MAVS-mediated innate immune response by ASC.

Authors:  Yue Han; Xiang He; Congwen Wei; Ting Song; Ling Zou; Zihui Li; Jiazhou Ye; Lunan Qi; Lequn Li; Hui Zhong; Feixiang Wu
Journal:  Mol Cell Biochem       Date:  2017-12-26       Impact factor: 3.396

8.  Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27.

Authors:  Qingliang Zheng; Jin Hou; Ye Zhou; Yingyun Yang; Bing Xie; Xuetao Cao
Journal:  Cell Res       Date:  2015-09-11       Impact factor: 25.617

Review 9.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

Review 10.  Type I interferon and lymphangiogenesis in the HSV-1 infected cornea - are they beneficial to the host?

Authors:  Katie Bryant-Hudson; Christopher D Conrady; Daniel J J Carr
Journal:  Prog Retin Eye Res       Date:  2013-07-19       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.